financetom
Business
financetom
/
Business
/
Boeing takes near $5 billion hit on 777X program
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Boeing takes near $5 billion hit on 777X program
Oct 29, 2025 5:00 AM

(Reuters) -Boeing ( BA ) reported a charge of nearly $5 billion related to delays in its 777X jet program on Wednesday, but its quarterly loss narrowed on improved production and deliveries of commercial aircraft.

Despite progress on the 737 MAX, the planemaker continues to face setbacks with its 777X program. It said on Wednesday the first delivery of the 777X has been pushed to 2027, delaying the timeline further from the previously expected 2026 launch.

The aircraft was originally slated for delivery in 2020 when the program was launched in 2013.

Last month, CEO Kelly Ortberg said the company was behind schedule in certifying the jet, saying a "mountain of work" needed to be done.

He, however, said no new technical problems had been identified.

Including charges disclosed on Wednesday, Boeing ( BA ) has taken about $15 billion in charges related to the 777X program.

After years of grappling with quality issues and production delays on its flagship 737 MAX, Boeing ( BA ) cautiously ramped up monthly output in 2025.

Earlier this month, the company received the long-awaited approval from the U.S. Federal Aviation Administration to increase 737 MAX production to 42 jets per month, easing a cap of 38 that had been in place since January 2024.

That cap was imposed following a mid-air panel blowout on a nearly new aircraft.

The planemaker posted a net loss of $5.34 billion, or $7.14 per share, for the quarter through September, compared with a loss of $6.17 billion, or $9.97 per share, a year earlier.

Boeing ( BA ) delivered 55 jets in September, marking its strongest performance for that month since 2018. This was a significant jump from the 33 deliveries recorded a year earlier, when a strike involving 33,000 factory workers in the Pacific Northwest disrupted production.

Deliveries are closely watched by Wall Street, as planemakers typically receive the bulk of their payments upon handing over the jets to customers, making deliveries a key indicator of revenue and cash flow.

(Reporting by Shivansh Tiwary in Bengaluru; Editing by Sriraj Kalluvila)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Global Business Travel Q3 revenue up 13%, beats estimates
Global Business Travel Q3 revenue up 13%, beats estimates
Nov 10, 2025
Overview * Global Business Travel ( GBTG ) Q3 revenue grows 13%, beating analyst expectations * Adjusted EBITDA for Q3 rises 9%, in line with expectations * Company completed CWT acquisition, enhancing revenue growth and cost transformation Outlook * Company raises FY 2025 guidance to revenue growth of approximately 12% * Company expects FY 2025 adjusted EBITDA between $523 mln...
Tegna Q3 revenue falls 19%, misses estimates
Tegna Q3 revenue falls 19%, misses estimates
Nov 10, 2025
Overview * Tegna ( TGNA ) Q3 revenue fell 19%, missing analyst expectations * Adjusted EBITDA for Q3 beats analyst estimates, aided by cost-cutting initiatives * Nexstar to acquire Tegna ( TGNA ) for $6.2 bln, pending regulatory approval Outlook * TEGNA ( TGNA ) will not provide forward-looking financial guidance due to pending Nexstar acquisition * TEGNA ( TGNA...
Chipmaker Ceva's Q3 revenue beats estimates on strong licensing growth
Chipmaker Ceva's Q3 revenue beats estimates on strong licensing growth
Nov 10, 2025
Overview * Ceva Q3 2025 revenue slightly beats analyst expectations, driven by strong licensing growth * AI processor licensing contributed one-third of licensing revenue, marking a major milestone * Company repurchased 40,295 shares for $1 mln, focusing on profitability improvement Outlook * Ceva ( CEVA ) highlights AI processor licensing as a key revenue contributor * Company focuses on disciplined...
Akebia Therapeutics Q3 revenue rises
Akebia Therapeutics Q3 revenue rises
Nov 10, 2025
Overview * Akebia Q3 2025 total revenue grows to $58.8 mln, driven by Vafseo and Auryxia sales * Net income for Q3 2025 beats analyst expectations, marking a turnaround from last year * Company expects Vafseo patient access to grow to 275,000 by year-end Outlook * Akebia expects Vafseo prescribing access to reach 275,000 patients by year-end * Company anticipates...
Copyright 2023-2026 - www.financetom.com All Rights Reserved